Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. International Journal of Antimicrobial Agents
Recommended Dosage IV or IM Pediatric Patients
(aged 3 months to 12 years)
Recommended Treatment Duration
Complicated intra-abdominal infections
15 mg/kg twice dailyc
5 to 14 days
Complicated skin/skin-structure infections
15 mg/kg twice dailyc
7 to 14 days
Community-acquired pneumonia
15 mg/kg twice dailyc
10 to 14 daysd
Complicated urinary tract infections
15 mg/kg twice dailyc
10 to 14 daysd
Acute Pelvic Infections
15 mg/kg twice dailyc
3 to 10 days
Infectionsb
Recommended Dosage Adult & Pediatric Patients
(aged 13 years and older)
Recommended Treatment Duration
Complicated intra-abdominal infections
1 g once daily
5 to 14 days
Complicated skin/skin-structure infections
1 g once daily
7 to 14 days
Community-acquired pneumonia
1 g once daily
10 to 14 daysd
Complicated urinary tract infections
1 g once daily
10 to 14 daysd
Acute Pelvic Infections
1 g once daily
3 to 10 days
IV = intravenous; IM = intramuscular
a Defined as creatinine clearance >90 mL/min/1.73 m2 b Due to the designated pathogens c Not to exceed 1 g/day d Duration includes a possible switch to an appropriate oral therapy after at least 3 days of parenteral therapy once clinical improvement has been demonstrated.
INVANZ® is not recommended in infants younger than 3 months, as no data are available.
